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Regulation of b1-integrin-mediated cell adhesion by the Cbl
adaptor protein
Traci Zell*, Christopher S. Warden*, Anissa S.H. Chan*, Molly E. Cook†, 
Cheryl L. Dell†, Stephen W. Hunt III† and Yoji Shimizu*
Background: Leukocyte activation results in a rapid increase in adhesion to the
extracellular matrix due to the activation of β1 integrin receptors. A role for
phosphatidylinositol (PI) 3-kinase in integrin activation has been proposed, as
activation of integrins by many receptors can be blocked by PI 3-kinase inhibitors.
One receptor that regulates integrins is the CD28 surface antigen; here, we
investigated the mechanisms responsible for CD28-mediated integrin activation.
Results: CD28-mediated integrin activation was blocked by mutation of the
binding site for the p85 catalytic subunit of PI 3-kinase in the CD28
cytoplasmic domain, and by expression of a dominant-negative form of the p85
subunit. Substitution of the Src homology 2 (SH2)-binding motif in the CD28
cytoplasmic domain for the corresponding motif in the CD28-related CTLA-4
surface antigen also blocked integrin activation but did not affect the
recruitment and activation of PI 3-kinase. Mutations of the CD28 cytoplasmic
domain that blocked integrin activation also impaired the tyrosine
phosphorylation of the Cbl adaptor protein and the activation of the PI 3-kinase
that was associated with Cbl. This Cbl-associated PI 3-kinase was distinct from
the PI 3-kinase that coprecipitated with the CD28 cytoplasmic domain. CD28-
mediated activation of β1 integrins was inhibited by expression of a mutant Cbl
protein that shows reduced association with PI 3-kinase. 
Conclusions: Cbl is required for PI-3-kinase-dependent regulation of integrin
receptors by CD28. Furthermore, CD28 is coupled to two distinct pools of PI
3-kinase, one directly associated with the CD28 cytoplasmic tail and the other
associated with Cbl.
Background
Activation of leukocytes can result in rapid changes in the
functional activity of adhesion receptors expressed on the
cell surface [1]. Although resting T lymphocytes express
integrins such as α4β1, α5β1, and αLβ2 on their cell
surface, these cells bind poorly to integrin extracellular
matrix ligands and cellular counter-receptors for these
ligands. However, activation of T lymphocytes results in a
rapid increase in integrin-mediated adhesion which does
not involve an increase in the cell surface expression of
integrins [2–4]. This mode of adhesion regulation plays a
critical role in the interaction between antigen-specific
lymphocytes and antigen-presenting cells, the migration
of lymphocytes through lymphoid tissue, and the multi-
step cascade that allows for leukocyte exit from the blood-
stream via interactions with vascular endothelium [1,5].
Engagement of several different receptors on the T lym-
phocyte surface can generate intracellular signals that acti-
vate integrin-mediated adhesion. These receptors include
the antigen-specific complex containing the T-cell recep-
tor and the CD3 group of signaling proteins, T-cell 
coreceptors such as CD2 and CD7, and some serpentine
G-protein-coupled chemokine receptors [2–4,6,7]. The
focus of this report is on one such regulator of integrin
activation, the CD28 surface antigen. CD28 stimulation is
a critical component of T-cell signaling responses that
lead to proliferation and cytokine production [8]. The
cytoplasmic tail of CD28 contains a binding motif,
Y173MNM (single-letter amino acid code), for proteins
containing Src homology 2 (SH2) domains. CD28 engage-
ment leads to phosphorylation of Tyr173 and the subse-
quent association of several SH2-domain-containing
proteins with CD28, including the Grb2–Sos adaptor
protein complex, and the p85 regulatory subunit of the
lipid kinase phosphatidylinositol (PI) 3-kinase [9–11].
Genetic and pharmacological studies have suggested a
role for CD28-mediated activation of PI 3-kinase in CD28
signaling in some, but not all, cell systems [11–16].
We have recently proposed that PI 3-kinase has a central
role in the regulation of integrin-mediated adhesion by
CD28 and other integrin regulators [17]. One mechanism
by which these integrin regulators are coupled to 
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PI-3-kinase-dependent pathways of integrin activation
may involve the assembly of multiprotein intracellular
complexes mediated by adaptor proteins upon cell stimu-
lation. One such adaptor protein is p120cbl (Cbl), a
120 kDa cytoplasmic protein that contains numerous tyro-
sine residues and proline-rich regions that could poten-
tially interact with proteins containing SH2 and SH3
domains [18]. Rapid tyrosine phosphorylation of Cbl has
been observed following stimulation of several cell surface
receptors, including the T-cell receptor [19], surface
immunoglobulin [20], the FcεRI receptor (for the constant
region of immunoglobulin E) [21], and the epidermal
growth factor receptor [22]. Additionally, Cbl associates
with many adaptor and/or signaling molecules, including
Grb2 [20,23,24], Nck [25], Crk [24], Shc [20], p59fyn
[20,23], Syk [20], p85 [20,23,26], and 14-3-3 proteins [27].
A role for Cbl in regulation of the Ras pathway and the
Syk tyrosine kinase has also been proposed [21,28,29].
In this report, we demonstrate that CD28-mediated acti-
vation of β1 integrins requires PI 3-kinase, but does not
require association of PI 3-kinase with the SH2-binding
motif in the CD28 cytoplasmic domain. Rather, we find
that this SH2-binding motif has a central role in CD28-
mediated tyrosine phosphorylation of Cbl, which results in
recruitment and activation of PI 3-kinase. As a mutant
form of Cbl with reduced ability to bind to p85 can inhibit
CD28-mediated integrin activation, we suggest that Cbl
has a specific role in regulating cell adhesion.
Results and discussion
CD28-mediated activation of b1 integrin function is
dependent on PI 3-kinase
An expression construct encoding a chimeric receptor con-
sisting of the CD2 extracellular and transmembrane
domains fused in-frame to the CD28 cytoplasmic domain
(CD2/28) was expressed in the HL60 myelomonocytic cell
line (Figure 1a), which expresses the α4β1 and α5β1 inte-
grins. This cell line exhibits activation-dependent adhe-
sion to fibronectin, as demonstrated by the rapid increase
in HL60 adhesion to fibronectin following stimulation
with the phorbol ester phorbol myristate acetate (PMA) or
direct activation of β1 integrins with the β1-integrin-spe-
cific monoclonal antibody TS2/16 (Figure 1b). Stimulation
of CD2/28-expressing HL60 transfectants via cross-linking
of the CD2/28 chimera with a CD2-specific monoclonal
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Figure 1
The Y173F mutation in the CD28 cytoplasmic
tail inhibits β1 integrin activation, p85
recruitment and PI 3-kinase activation.
(a) Flow cytometric analysis of HL60
transfectants expressing CD2/28,
CD2/28Y173F, CD2/28Y188F,
CD2/28Y191F and CD2/28Y200F.
Expression of CD2/28 and β1 integrin was
assessed by single-color flow cytometry as
described [38]. Binding of a negative control
monoclonal antibody is shown in the open
profiles in each panel of the histograms. All
transfectants also expressed comparable
levels of α4 and α5 integrin (data not shown).
(b) Adhesion of HL60 transfectants to
fibronectin (FN; 1 µg per well) was assessed
as previously described [13] after no
stimulation, or stimulation for 10 min at 37°C
with cross-linking using the negative control
monoclonal antibody 10F7, cross-linking of
CD2/28 with the CD2-specific monoclonal
antibody TS2/18 or 10 ng/ml PMA. (c) The
Y173F mutation inhibits CD2/28-mediated
recruitment of p85. Cells were either left
unstimulated or were stimulated for 5 min with
the CD2-specific monoclonal antibody
TS2/18, and the CD2/28 receptor was
immunoprecipitated from cell lysates and
subjected to SDS–PAGE. Western blots
were probed with an anti-p85 antibody.
(d) The Y173F mutation inhibits CD2/28-
mediated activation of associated PI 3-kinase.
Cells were either left unstimulated or were
stimulated for 5 min with the CD2-specific
monoclonal antibody TS2/18, and the
CD2/28 receptor was immunoprecipitated
from cell lysates. PI 3-kinase activity in cell
lysates was measured as previously described
[38] by in vitro phosphorylation of the PI 3-
kinase substrate — PI — followed by thin layer
chromatography (TLC) and visualization of the
labeled PI product (PI 3-phosphate, PIP) by
autoradiography. The fold increase in PI 3-
kinase activity upon stimulation for each
transfectant was determined by
phosphorimager analysis of the TLC plate.
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antibody also resulted in increased β1-integrin-mediated
adhesion to fibronectin (Figure 1b). This was accompa-
nied by increased binding of the p85 regulatory subunit of
PI 3-kinase to CD2/28 (Figure 1c), and increased PI 3-
kinase activity in CD2/28 immunoprecipitates (Figure 1d). 
A role for PI 3-kinase in CD28-mediated activation of β1
integrin function was tested by transiently expressing a
dominant-negative p85 construct tagged with green fluores-
cent protein (GFP–∆p85; Figure 2a). The GFP tag enabled
us to use flow cytometry to quantitate the adhesion of the
subpopulation of transiently transfected cells expressing
GFP–∆p85, as well as the larger population of transfected
cells in the same sample that did not express GFP–∆p85
(Figure 2a) [6]. CD2/28-induced adhesion of HL60 cells to
fibronectin was inhibited in transiently transfected cells
expressing the GFP–∆p85 construct (Figure 2b). The
inhibitory effects of GFP–∆p85 were not due to global 
inhibition of integrin function or cell adhesive capabilities,
as integrin activation induced by PMA or direct β1 integrin
stimulation was not inhibited by GFP–∆p85. Furthermore,
expression of GFP itself did not inhibit adhesion induced
by either CD2/28 stimulation, PMA stimulation or direct β1
integrin activation (Figure 2b). This suggests that the
inhibitory effect of the GFP–∆p85 construct on CD2/28-
mediated activation of β1 integrins was due specifically to
the expression of the dominant-negative p85 protein. 
To determine the ability of GFP–∆p85 to associate with
the CD28 cytoplasmic tail, HL60(CD2/28) cells were tran-
siently transfected with GFP–∆p85 and sorted by flow
cytometry to isolate cells expressing GFP–∆p85
(GFP–∆p85+ cells). The resulting population of cells
expressed low, but uniform levels of GFP–∆p85 (mean
channel fluorescence of 37). Stimulation of CD2/28
resulted in association of the 115 kDa GFP–∆p85 fusion
protein with the CD2/28 chimera (Figure 2c). The rela-
tively low level of GFP–∆p85 expression in the sorted
cells allowed for some endogenous p85 also to associate
with CD2/28 in this experiment.
We produced additional stable transfectants expressing
CD2/28 chimeras where each of the four tyrosine residues
in the CD28 cytoplasmic domain was mutated to pheny-
lalanine. Each mutant chimera was expressed in HL60
cells at levels comparable to those for CD2/28 (Figure 1a).
The only mutation that affected CD28-mediated activa-
tion of adhesion was the tyrosine to phenylalanine muta-
tion at position 173 in the YMNM SH2-binding site of the
CD28 cytoplasmic domain (CD2/28Y173F; Figure 1b).
This mutation also inhibited activation-induced associa-
tion of p85 (Figure 1c) and the subsequent activation of PI
3-kinase associated with the CD28 cytoplasmic tail
(Figure 1d). Thus, these results suggest a critical role for
the YMNM SH2-binding motif in the CD28 cytoplasmic
domain in CD28-mediated integrin activation.
Identification of a CD28 cytoplasmic domain mutation that
blocks integrin activation but not coupling to PI 3-kinase
To further characterize the role of the YMNM SH2-
binding motif in coupling CD28 to PI 3-kinase and inte-
grin activation, the YMNM sequence found in the CD28
cytoplasmic tail was replaced with the sequence YVKM
creating CD2/28YVKM. We chose this sequence because it
is found in the cytoplasmic domain of the CD28-related
receptor CTLA-4, which has been shown to be capable of
associating with PI 3-kinase upon activation [30]. HL60
transfectants were obtained that expressed CD2/28YVKM
on the cell surface at levels comparable to those for
CD2/28 (Figure 3a). Like wild-type CD28, activation of
CD2/28YVKM resulted in the recruitment of p85 and acti-
vation of PI 3-kinase coprecipitated with the receptor
(Figure 3b). However, activation of CD2/28YVKM failed
to induce increased adhesion to fibronectin at any of the
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Figure 2
Dominant-negative p85 blocks CD2/28-mediated activation of β1-
integrin-mediated adhesion. (a) Expression of GFP and a GFP–∆p85
fusion protein in HL60(CD2/28) cells. Fluorescence of untransfected
HL60(CD2/28) cells is also shown. The markers in each panel indicate
the markers used to assess the adhesion, shown in (b), of GFP– and
GFP+ cells. (b) Adhesion of transiently transfected HL60(CD2/28)
cells expressing either GFP or GFP–∆p85 to fibronectin (FN; 1 µg per
well) was assessed as previously described [6]. The percentage of
cells adhering to fibronectin was quantified by flow cytometry [6] and
the results indicate the percentage adhesion of the GFP– and GFP+
cells in each transfected population under each stimulation condition
tested. (c) HL60(CD2/28) cells transiently expressing GFP–∆p85
were sorted for GFP+ cells. The resulting population of sorted cells
had a mean channel fluorescence of 37, compared with a mean
channel fluorescence of 4 for untransfected HL60(CD2/28) cells. The
CD2/28 receptor was either immunoprecipitated from unstimulated
sorted cells or from sorted cells that had been stimulated for 5 min
with the CD2-specific monoclonal antibody TS2/18 and the
immunoprecipitates were subjected to SDS–PAGE. Western blots
were probed with an anti-p85 antibody.
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time points tested (Figure 3c). This was not due to defects
in β1 integrin expression in this transfectant, since β1 inte-
grin expression levels did not differ from HL60(CD2/28)
transfectants and untransfected HL60 cells (Figures 1a,3a).
Furthermore, β1 integrin function was not impaired in
HL60(CD2/28YVKM) transfectants, since PMA stimula-
tion and direct activation of β1 integrins with the TS2/16
monoclonal antibody induced increases in adhesion com-
parable to those seen with HL60(CD2/28) transfectants
(Figure 3c). Thus, these results suggest that recruitment of
PI 3-kinase to the CD28 cytoplasmic tail and subsequent
PI 3-kinase activation is not sufficient to activate integrins. 
CD28 cytoplasmic domain mutations that block integrin
activation also impair tyrosine phosphorylation of Cbl
Our results with the CD2/28YVKM chimeric receptor
suggest the possibility that the CD28 cytoplasmic tail acti-
vates integrins via a mechanism independent of direct
recruitment of PI 3-kinase to CD28. To investigate this
hypothesis, we examined the ability of CD28 stimulation
to induce association and activation of PI 3-kinase with
known adaptor proteins. As Cbl has previously been identi-
fied as a substrate for tyrosine kinase activity stimulated by
CD28 ligation [31], we immunoprecipitated cell lysates
with a Cbl-specific antibody and immunoblotted with an
anti-phosphotyrosine monoclonal antibody. Figure 4a
shows that CD2/28 cross-linking resulted in tyrosine phos-
phorylation of Cbl. Immunoblotting of the same anti-Cbl
immunoprecipitates with a p85-specific antibody demon-
strated that CD2/28 cross-linking resulted in association of
the p85 subunit of PI 3-kinase with tyrosine phosphory-
lated Cbl (Figure 4a). To determine if the induced associa-
tion of p85 with Cbl resulted in increased Cbl-associated PI
3-kinase activity, we performed PI 3-kinase activity assays
with anti-Cbl immunoprecipitates from HL60(CD2/28)
cells. Figure 4b shows that stimulation of the CD2/28
chimeric receptor induced a rapid and transient increase in
Cbl-associated PI 3-kinase activity. Thus, stimulation of
the CD2/28 chimera results in tyrosine phosphorylation of
Cbl, the coprecipitation of p85 with tyrosine-phosphory-
lated Cbl (Figure 4a), and increased PI 3-kinase activity in
anti-Cbl immunoprecipitates (Figure 4b). 
Sequential immunoprecipitation experiments were per-
formed to determine if CD28 stimulation resulted in the
recruitment of a Cbl–p85 complex to the CD28 cytoplas-
mic domain. Lysates from unstimulated and CD2/28-stim-
ulated HL60(CD2/28) transfectants were first depleted of
CD2/28 chimeric protein by three sequential immunopre-
cipitations with a CD2-specific monoclonal antibody, fol-
lowed by immunoprecipitation with a Cbl-specific
antibody. Figure 4c shows that Cbl was not detected in
immunoprecipitates containing the CD2/28 chimera. In
addition, Cbl was immunoprecipitated from lysates of
unstimulated and CD2/28-stimulated cells that were
extensively precleared of the CD2/28 chimera (Figure 4c).
Immunodepletion of CD2/28 from cell lysates also did not
affect the amount of PI 3-kinase activity associated with
Cbl (data not shown). Although Grb2 has been reported to
associate with Cbl [20,23,24] and CD28 [10], we were
unable to detect the association of Grb2 with the CD28
cytoplasmic domain in our system (data not shown).
These results suggest that CD2/28 stimulation does not
result in the association of Cbl with the CD28 cytoplasmic
domain and that the PI 3-kinase activity associated with
Cbl following CD2/28 stimulation is distinct from the PI
3-kinase activity directly associated with the receptor
itself. Thus, activation by CD28 of two distinct pools of 
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Figure 3
The YVKM SH2-binding motif recruits and
activates PI 3-kinase but fails to activate β1
integrins. (a) Flow cytometric analysis of HL60
transfectants expressing the CD2/28YVKM
receptor. Expression of CD2/28 and β1
integrin was assessed by single-color flow
cytometry as described [38]. Binding of a
negative control monoclonal antibody is shown
in the open profile in each panel. 
(b) Stimulation of the CD2/28YVKM receptor
results in p85 recruitment and PI 3-kinase
activation. The CD2/28 receptor was
immunoprecipitated from unstimulated
HL60(CD2/28YVKM) cells (–) or
HL60(CD2/28YVKM) cells stimulated for 5 or
10 min with the CD2-specific monoclonal
antibody TS2/18 and subjected to
SDS–PAGE. Western blots were probed with
an anti-p85 antibody. CD2/28
immunoprecipitates from unstimulated and
stimulated HL60(CD2/28YVKM) cells were
analyzed for PI 3-kinase activity as previously
described [38]. The fold increase in PI 3-kinase
activity upon stimulation of CD2/28YVKM was
determined by phosphorimager analysis of the
TLC plate. (c) The adhesion of HL60(CD2/28)
and HL60(CD2/28YVKM) cells to fibronectin
(FN; 1 µg per well) was assessed at the
indicated times after no stimulation, or
following stimulation with 10 ng/ml PMA, the
CD2-specific monoclonal antibody TS2/18,
the negative control monoclonal antibody 10F7
or the activating β1-integrin-specific
monoclonal antibody TS2/16.
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PI 3-kinase may provide additional levels of complexity
and specificity in the regulation of downstream responses
that are dependent on PI 3-kinase activation. As several
isoforms of PI 3-kinase have been identified [32], it is also
possible that activation of different PI 3-kinase isoforms
may be a reflection of these distinct pools of PI 3-kinase. 
We next examined the effect of various CD28 cytoplasmic
domain mutations on CD28-mediated tyrosine phosphory-
lation of Cbl and association and activation of PI 3-kinase
with Cbl. Anti-phosphotyrosine immunoblotting demon-
strated that mutations of the tyrosine residues at positions
188, 191 and 200 partially reduced the ability of the
CD2/28 chimera to induce tyrosine phosphorylation of
Cbl (Figure 4a). However, this reduction in tyrosine phos-
phorylation of Cbl by the Y188F, Y191F and Y200F muta-
tions had little effect on the amount of p85 detected in
anti-Cbl immunoprecipitates upon CD2/28 cross-linking.
In contrast, the Y173F substitution resulted in dramati-
cally reduced tyrosine phosphorylation of Cbl and p85
recruitment upon chimera cross-linking (Figure 4a).
These results demonstrate a role for tyrosine 173 in
CD28-mediated tyrosine phosphorylation of Cbl and
recruitment of p85 to Cbl, perhaps by regulating the acti-
vation of a tyrosine kinase involved in Cbl phosphoryla-
tion. Alternatively, activation of PI 3-kinase by the CD28
cytoplasmic domain itself may play a role in activating a
downstream kinase, as the lipid products of PI 3-kinase
are capable of directly interacting with kinases containing
SH2 and pleckstrin homology domains [33,34]. 
The YVKM substitution also significantly inhibited tyro-
sine phosphorylation of Cbl (Figure 4d), as well as recruit-
ment and activation of PI 3-kinase in anti-Cbl
immunoprecipitates (Figure 4b,d). Thus, receptors that
were not able to mediate integrin activation
(CD2/28Y173F and CD2/28YVKM) exhibited dramati-
cally reduced ability to induce tyrosine phosphorylation of
Cbl and activate Cbl-associated PI 3-kinase. 
Inhibition of CD28-mediated activation of b1-integrin-
mediated adhesion by a Cbl mutant
To examine the role of Cbl in integrin activation, we tran-
siently expressed fusion constructs encoding GFP-tagged
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Figure 4
CD28-mediated tyrosine phosphorylation of
Cbl, and activation of Cbl-associated PI 3-
kinase. (a) The Y173F mutation inhibits
CD2/28-mediated tyrosine phosphorylation of
Cbl and coprecipitation of p85 with Cbl. Cells
were either left unstimulated (–) or were
stimulated for 5 or 10 min with the CD2-
specific monoclonal antibody TS2/18, and Cbl
was immunoprecipitated from cell lysates and
subjected to SDS–PAGE. Western blots were
sequentially probed with the anti-
phosphotyrosine monoclonal antibody 4G10
(anti-PTyr), an anti-Cbl antibody, and an anti-
p85 antibody. (b) Cbl immunoprecipitates from
unstimulated and stimulated HL60(CD2/28)
and HL60(CD2/28Y173F) cells were analyzed
for PI 3-kinase activity as previously described
[38]. The fold increase in PI 3-kinase activity in
lysates from unstimulated cells (–), and lysates
from cells stimulated by CD2/28 cross-linking
for 1 min, 5 min, 10 min and 20 min was
calculated by assigning the density volume of
the unstimulated sample a value of one.
Results shown are average fold increases in PI
3-kinase activity from three independent
experiments ± the standard deviation. (c) Cbl
does not coprecipitate with the CD2/28
receptor. HL60(CD2/28) cells were either left
unstimulated or were stimulated by CD2/28
cross-linking for 5 min and then lysed. Lysates
were first depleted of CD2/28 chimeric protein
by three sequential immunoprecipitations with
a CD2-specific monoclonal antibody (steps
1–3) followed by immunoprecipitation with
anti-Cbl polyclonal antibody (step 4). Samples
from each step were subjected to SDS–PAGE
and western blots were sequentially probed
with an anti-CD2 monoclonal antibody and an
anti-Cbl antibody. The band labeled Ig
represents the immunoprecipitating antibody
that is detected by the western blotting
procedure. (d) The YVKM SH2-binding motif
inhibits Cbl tyrosine phosphorylation and p85
recruitment. HL60(CD2/28) and
HL60(CD2/28YVKM) cells were either left
unstimulated (–) or were stimulated with the
CD2-specific monoclonal antibody TS2/18,
and Cbl was immunoprecipitated from cell
lysates and subjected to SDS–PAGE.
Western blots were sequentially probed with
the anti-phosphotyrosine monoclonal antibody
4G10 (anti-PTyr), an anti-Cbl antibody and an
anti-p85 antibody.
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wild-type Cbl and GFP-tagged 70Z/3-Cbl, a mutant form of
Cbl that contains a 17 amino acid deletion in the zinc ring
finger region of the Cbl protein [35,36], in HL60(CD2/28)
cells. The 70Z/3-Cbl mutant exhibits hyperphosphorylation
but reduced association with p85 upon CD28 stimulation.
Expression of the GFP–Cbl proteins was obtained in
20–30% of the transfected cell population (Figure 5a) and
did not affect levels of β1 integrin expression (data not
shown). Anti-GFP immunoprecipitates were analyzed by
western blotting to determine the effects of CD2/28 stimu-
lation on tyrosine phosphorylation of GFP–Cbl and associa-
tion of p85 with GFP–Cbl. As seen with endogenous Cbl,
CD2/28 stimulation resulted in increased tyrosine phospho-
rylation of Cbl and recruitment of p85 (Figure 5b). The
70Z/3-Cbl protein exhibited significant levels of basal tyro-
sine phosphorylation in unstimulated HL60(CD2/28) cells.
Furthermore, CD2/28 stimulation resulted in much
stronger tyrosine phosphorylation of 70Z/3-Cbl than wild-
type Cbl (Figure 5b). However, this was not accompanied
by increased association of p85 with 70Z/3-Cbl. In fact,
when normalized to the amount of Cbl immunoprecipitated
in each sample, there was reduced association of p85 with
70Z/3-Cbl compared with wild-type Cbl in CD2/28-stimu-
lated cells. Similarly, even though 70Z/3-Cbl was hyper-
phosphorylated in unstimulated cells, there was little
detectable coprecipitating p85. Thus, these results suggest
that the deletion in 70Z/3-Cbl impairs the ability of p85 to
associate with Cbl following CD2/28 stimulation.
In adhesion assays, expression of GFP–Cbl had no effect
on the adhesion of unstimulated cells or cells stimulated
by CD2/28 activation, PMA or direct activation of β1 inte-
grins (Figure 5c). In contrast, expression of GFP–70Z/3-
Cbl specifically inhibited adhesion induced by stimulation
of the CD2/28 receptor. Gating on transiently transfected
cells expressing varying levels of GFP–70Z/3-Cbl, shown
in Figure 5a, also revealed a dose-dependent inhibitory
effect of 70Z/3-Cbl on CD2/28-mediated adhesion in the
various populations (Figure 5c). This therefore suggests
that 70Z/3-Cbl has a dominant-negative effect on integrin
activation induced by the CD28 cytoplasmic domain.
The inhibitory effect of GFP–70Z/3-Cbl on integrin func-
tion was specific for signaling induced by CD2/28, as
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Figure 5
Inhibition of CD28-mediated activation of β1
integrins by 70Z/3-Cbl. (a) Expression of
GFP–Cbl and GFP–70Z/3-Cbl in
HL60(CD2/28) cells. The fluorescence of
untransfected HL60(CD2/28) cells is also
shown. The markers labeled 0–4 in each
panel indicate the markers used to assess the
adhesion, shown in (c), of GFP– cells and
cells expressing varying levels of GFP. 
(b) The 70Z/3-Cbl mutant exhibits
hyperphosphorylation on tyrosine residues but
reduced ability to coprecipitate with p85 upon
CD2/28 stimulation. Unstimulated and
CD2/28-stimulated HL60(CD2/28) cells
transiently transfected with GFP, GFP–Cbl, or
GFP–70Z/3-Cbl were immunoprecipitated
with an anti-GFP antibody. Western blots
were sequentially probed with the anti-
phosphotyrosine monoclonal antibody 4G10
(anti-PTyr), an anti-Cbl antibody, and an anti-
p85 antibody. (c) The 70Z/3-Cbl mutant
exhibits dose-dependent inhibition of
CD2/28-mediated activation of β1-integrin-
mediated adhesion. Adhesion of transiently
transfected HL60(CD2/28) cells expressing
either GFP–Cbl or GFP–70Z/3-Cbl to
fibronectin (FN; 1 µg per well) was assessed
as previously described [6]. Cells were either
left unstimulated (–) or were stimulated with
the CD2-specific monoclonal antibody
TS2/18, PMA or the activating β1-integrin-
specific monoclonal antibody TS2/16. The
percentage of cells adhering to fibronectin
was quantified by flow cytometry and the
results show the percentage adhesion of the
GFP– cells (0) and cells with increasing levels
of GFP expression (1–4) based on the
markers in (a). (d) The 70Z/3-Cbl mutant
does not inhibit CD64-mediated activation of
β1-integrin-mediated adhesion. Cells were
either left unstimulated (–) or were stimulated
with the CD2-specific monoclonal antibody
TS2/18 or the CD64-specific monoclonal
antibody 32.2. Adhesion of transiently
transfected HL60(CD2/28) cells expressing
GFP–70Z/3-Cbl to fibronectin (1 µg per well)
was assessed as in (c). The percentage of
cells adhering to fibronectin was quantified by
flow cytometry and the results show the
percentage adhesion of the GFP– cells (0)
and cells with increasing levels of GFP
expression (1–4) based on markers similar to
those shown in (a).
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expression of GFP–70Z/3-Cbl did not affect adhesion
induced by PMA or the activating β1-integrin-specific
monoclonal antibody TS2/16 (Figure 5c). In addition,
stimulation of the CD64 (FcγRI) receptor, which activates
PI 3-kinase [37] and is expressed at moderate levels on
HL60 cells (data not shown), resulted in increased adhe-
sion of HL60 cells to fibronectin (Figures 2b,5d). Whereas
CD64-mediated activation of adhesion was also inhibited
by GFP–∆p85 (Figure 2b) and by the PI 3-kinase inhibitor
wortmannin (data not shown), it was unaffected by expres-
sion of 70Z/3-Cbl (Figure 5d). Thus, even though CD28
and CD64 both appear to use PI 3-kinase to activate adhe-
sion, there is a differential role for Cbl in regulating adhe-
sion by these two receptors. This suggests that the role of
Cbl in regulation of integrin-mediated adhesion is depen-
dent on the nature of the activating stimulus.
We have previously proposed a central role for PI 3-kinase
in the activation of integrin-mediated adhesion induced
by the CD28 antigen, as well as other receptors that are
capable of activating integrin function [17]. The ability of
a dominant-negative form of the p85 subunit of PI 
3-kinase to specifically inhibit CD28-mediated activation
of β1-integrin-mediated cell adhesion is consistent with
this hypothesis. As CD28 associates with and activates PI
3-kinase via binding of the p85 subunit to the tyrosine-
phosphorylated YMNM SH2-binding motif [9–11], we
reasoned that mutations in the CD28 cytoplasmic domain
that inhibit the direct recruitment of PI 3-kinase to CD28
should also block CD28-mediated activation of β1 inte-
grins. The Y173F mutation in the SH2-binding motif
inhibited CD28-induced association and recruitment of 
PI 3-kinase to CD28, and also blocked CD28-induced
activation of integrin-mediated adhesion. In contrast,
mutation of the remaining three tyrosine residues in the
CD28 cytoplasmic domain failed to inhibit either PI 
3-kinase recruitment to CD28 or integrin activation.
When we substituted the YMNM-binding motif with the
YVKM sequence found in the CTLA-4 antigen, however,
we observed that activation of PI 3-kinase directly copre-
cipitated with the CD2/28 chimera was uncoupled from
effects on integrin activation. Thus, the CD2/28YVKM
chimera retained an ability to associate with and activate
PI 3-kinase, but failed to activate integrin-mediated adhe-
sion. This result suggested that direct coupling of PI 
3-kinase to the CD28 cytoplasmic domain was not suffi-
cient to engage PI-3-kinase-dependent pathways of inte-
grin activation. We propose instead that Cbl may be
involved as an intracellular adaptor that is specifically
involved in coupling CD28 to a pool of PI 3-kinase that
can be distinguished biochemically and functionally from
the PI 3-kinase that is coprecipitated with the CD28 cyto-
plasmic domain itself. Several lines of evidence support
this model. First, CD28 ligation has been shown to result
in tyrosine phosphorylation of Cbl [31]. Second, tyrosine
phosphorylation of Cbl has been shown in many cell
systems to result in the association of p85 with Cbl
[20,23,26]. Third, the two CD28 cytoplasmic domain
mutations that block CD28-induced activation of integrin-
mediated adhesion, namely Y173F and YVKM, also
inhibit CD28-mediated association of p85 with Cbl.
Finally, CD28-mediated activation of integrin-mediated
adhesion can be specifically blocked by 70Z/3-Cbl, a
mutant form of Cbl that exhibits hyperphosphorylation
but reduced association with p85 upon CD28 stimulation.
Our results suggest a previously unappreciated function
for the Cbl adaptor protein — regulation of agonist-
induced cell adhesion. It is possible that other receptors
that activate integrins may also achieve similar effects via
tyrosine phosphorylation of Cbl and recruitment or activa-
tion of PI 3-kinase [6,17,38,39]. Other studies with Cbl
have analyzed its role in regulating Ras-dependent signal-
ing [40]. However, a consistent picture of how Cbl regu-
lates the Ras pathway has not emerged. Although
antisense-mediated inhibition of Cbl did not affect Ras
signaling initiated by the epidermal growth factor receptor
[41], expression of 70Z/3-Cbl enhanced Ras-dependent
activation of a reporter gene responsive to nuclear factor of
activated T cells (NFAT) [28]. Hyperphosphorylation of
Cbl, resulting in activation of the GTPase Rap1, may be
involved in the maintenance of clonal anergy in T cells via
negative regulation of Ras-dependent signaling [42]. Cbl
has also been implicated in the negative regulation of the
tyrosine kinase Syk [21]. The 70Z/3-Cbl mutant that we
used in this study has also been shown to have transform-
ing ability [35,36]. As changes in integrin-mediated adhe-
sion are a hallmark of cellular transformation, our studies
demonstrating an inhibitory effect of 70Z/3-Cbl on inte-
grin activation may also have relevance to the transform-
ing function of this Cbl mutant. 
Conclusions
We describe a novel role for the Cbl adaptor protein in
CD28-mediated regulation of β1-integrin-mediated cell
adhesion. CD28 stimulation results in the activation of two
distinct pools of PI 3-kinase, one associated with the CD28
cytoplasmic domain and one associated with tyrosine-phos-
phorylated Cbl. Although activation of both pools of PI 3-
kinase is dependent on the integrity of the SH2-binding
motif in the CD28 cytoplasmic domain, the ability of a
mutant form of Cbl to specifically block CD28-mediated
integrin activation suggests a role for Cbl in the regulation
of cell adhesion. These studies identify Cbl as a new intra-
cellular target for modulating integrin-mediated adhesion.
Materials and methods
Cell lines
The HL60 cell line was maintained in RPMI 1640 medium supple-
mented with 5% FCS (Atlanta Biologicals), L-glutamine, and peni-
cillin/streptomycin. During G418 selection after electroporation, the
concentration of FCS was increased to 10%.
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Flow cytometry and cell sorting
Single-color flow cytometric analysis was performed using the CD2-
specific monoclonal antibody TS2/18 (ATCC), β1-integrin-specific
monoclonal antibody TS2/16 (ATCC), α4-integrin-specific monoclonal
antibody NIH49d-1 (kind gift of S. Shaw), and α5-specific monoclonal
antibody P1D6 (GIBCO/BRL) and FITC-conjugated goat anti-mouse
IgG as previously described [13]. Data was acquired on a Becton
Dickinson FACScan and analyzed using Cellquest software.
HL60(CD2/28) cells transiently expressing the GFP–∆p85 construct
were sorted in the University of Minnesota Cancer Center Flow Cytom-
etry Core Facility with a FACSVantage using the enrich mode.
DNA constructs
All CD2/28 chimeric receptor constructs were made by RT–PCR gene
synthesis as previously described [13] using the pMH-NeoH.CD2
vector [38]. All plasmids were sequenced to confirm the fidelity of the
amplification reaction. The GFP–∆p85 construct has been described
previously [6]. The GFP–Cbl constructs were produced by subcloning
a 2.7 kb fragment containing wild-type Cbl or 70Z/3-Cbl (provided by
W. Langdon) in-frame into the SacII–SalI sites in the pEGFP-C2
carboxy-terminal protein fusion vector (Clontech). 
DNA-mediated gene transfer
Transfections were performed by electroporation as previously
described [38]. Stable G418-resistant cells were isolated by selection
in 1 mg/ml G418 and CD2-positive transfectants identified by flow
cytometry. A minimum of two or three subclones of each transfectant
expressing the same chimeric receptor were tested in subsequent
experiments. Expression of the correct CD2/28 receptor was verified
by western blotting and DNA sequencing. For transient transfections,
HL60(CD2/28) cells were transfected by electroporation as previously
described [6] and harvested for analysis in adhesion assays or by
western blotting 16–24 h after transfection.
Adhesion assays
Adhesion of HL60 transfectants to purified fibronectin was performed
using calcein–AM or 51Cr labeling as previously described [13]. For
transient transfectants expressing GFP fusion proteins, adhesion was
quantified by collection of adherent cells and analysis by flow cytometry
as previously described [6]. Stimulation conditions were 10 ng/ml
PMA, cross-linking of CD2/28 with the CD2-specific monoclonal anti-
body TS2/18 (ATCC) and goat anti-mouse IgG, cross-linking of CD64
with the CD64-specific monoclonal antibody 32.2 (ATCC) and goat
anti-mouse IgG, or direct activation of β1 integrins with the monoclonal
antibody TS2/16 (ATCC).
Western blotting
Immunoprecipitations were performed as previously described [38]
using either the anti-CD2 monoclonal antibody 35.1 (ATCC), an anti-
Cbl polyclonal antibody (Santa Cruz Biotechnology) or an anti-GFP
polyclonal antibody (Clontech). Immunoprecipitated proteins were sep-
arated on 7.5% SDS–polyacrylamide gels, transferred to Immobilon-P
membranes (Millipore), and immunoblotted with the indicated antibod-
ies followed by detection with enhanced chemiluminescence (Pierce).
Sequential immunodepletion experiments were performed as previously
described [43].
PI 3-kinase activity assays
PI 3-kinase activity in anti-CD2 or anti-Cbl immunoprecipitates was
assessed as previously described [38]. Radioactive lipid product was
visualized by autoradiography and quantified using a phosphorimager
(Molecular Dynamics).
Acknowledgements
We thank J. Peller of the University of Minnesota Cancer Center Flow
Cytometry Core Facility for expertise in cell sorting and M. Kasuga,
W. Ogawa, W. Langdon and S. Shaw for providing reagents. This work was
supported by grants to Y.S. from the NIH. Y.S. is the Harry Kay Chair of
Cancer Research at the University of Minnesota. 
References
1. Diamond MS, Springer TA: The dynamic regulation of integrin
adhesiveness. Curr Biol 1994, 4:506-517.
2. Dustin ML, Springer TA: T-cell receptor cross-linking transiently
stimulates adhesiveness through LFA-1. Nature 1989, 
341:619-624. 
3. Shimizu Y, van Seventer GA, Horgan KJ, Shaw S: Regulated
expression and binding of three VLA (b1) integrin receptors on T
cells. Nature 1990, 345:250-253.
4. van Kooyk Y, van de Wiel-van Kemenade P, Weder P, Kuijpers TW,
Figdor CG: Enhancement of LFA-1-mediated cell adhesion by
triggering through CD2 or CD3 on T lymphocytes. Nature 1989,
342:811-813.
5. Butcher EC, Picker LJ: Lymphocyte homing and homeostasis.
Science 1996, 272:60-66.
6. Chan ASH, Mobley JL, Fields GB, Shimizu Y: CD7-mediated
regulation of integrin adhesiveness on human T cells involves
tyrosine phosphorylation-dependent activation of
phosphatidylinositol 3-kinase. J Immunol 1997, 159:934-942.
7. Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher
EC: Chemokines and the arrest of lymphocytes rolling under flow
conditions. Science 1998, 279:381-384.
8. Rudd CE: Upstream-downstream: CD28 cosignaling pathways
and T cell function. Immunity 1996, 4:527-534.
9. Truitt KE, Hicks CM, Imboden JB: Stimulation of CD28 triggers an
association between CD28 and phosphatidylinositol 3-kinase in
Jurkat T cells. J Exp Med 1994, 179:1071-1076.
10. Raab M, Cai YC, Bunnell SC, Heyeck SD, Berg LJ, Rudd CE: p56Lck
and p59Fyn regulate CD28 binding to phosphatidylinositol 3-
kinase, growth factor receptor-bound protein GRB-2, and T cell-
specific protein-tyrosine kinase ITK: implications for T-cell
costimulation. Proc Natl Acad Sci USA 1995, 92:8891-8895.
11. Pagès F, Ragueneau M, Rottapel R, Truneh A, Nunes J, Imbert J, et al.:
Binding of phosphatidylinositol-3-OH kinase to CD28 is required
for T-cell signalling. Nature 1994, 369:327-329.
12. Ward SG, Wilson A, Turner L, Westwick J, Sansom DM: Inhibition of
CD28-mediated T cell costimulation by the phosphoinositide 
3-kinase inhibitor wortmannin. Eur J Immunol 1995, 25:526-532.
13. Zell T, Hunt SW III, Finkelstein LD, Shimizu Y: CD28-mediated
upregulation of b1 integrin-mediated adhesion involves
phosphatidylinositol 3-kinase. J Immunol 1996, 156:883-886.
14. Cai Y-C, Cefai D, Schneider H, Raab M, Nabavi N, Rudd CE:
Selective CD28pYMNM mutations implicate phosphatidylinositol
3-kinase in CD86-CD28-mediated costimulation. Immunity 1995,
3:417-426.
15. Truitt KE, Shi J, Gibson S, Segal LG, Mills GB, Imboden JB: CD28
delivers costimulatory signals independently of its association
with phosphatidylinositol 3-kinase. J Immunol 1995, 
155:4702-4710.
16. Crooks MEC, Littman DR, Carter RH, Fearon DT, Weiss A, Stein PH:
CD28-mediated costimulation in the absence of
phosphatidylinositol 3-kinase association and activation. Mol Cell
Biol 1995, 15:6820-6828.
17. Shimizu Y, Hunt SW III: Regulating integrin-mediated adhesion:
one more function for PI 3-kinase? Immunol Today 1996, 
17:565-573.
18. Langdon WY: The cbl oncogene: a novel substrate of protein
tyrosine kinases. Aust NZ J Med 1995, 25:859-864.
19. Donovan JA, Wange RL, Langdon WY, Samelson LE: The protein
product of the c-cbl protooncogene is the 120-kDa tyrosine-
phosphorylated protein in Jurkat cells activated via the T cell
antigen receptor. J Biol Chem 1994, 269:22921-22924.
20. Panchamoorthy G, Fukazawa T, Miyake S, Soltoff S, Reedquist K,
Druker B, et al.: p120cbl is a major substrate of tyrosine
phosphorylation upon B cell antigen receptor stimulation and
interacts in vivo with Fyn and Syk tyrosine kinases, Grb2 and Shc
adaptors, and the p85 subunit of phosphatidylinositol 3-kinase. J
Biol Chem 1996, 271:3187-3194.
21. Ota Y, Samelson LE: The product of the proto-oncogene c-cbl: a
negative regulator of the Syk tyrosine kinase. Science 1997,
276:418-420.
22. Galisteo ML, Dikic I, Batzer AG, Langdon WY, Schlessinger J:
Tyrosine phosphorylation of the c-cbl proto-oncogene protein
product and association with epidermal growth factor (EGF)
receptor upon EGF stimulation. J Biol Chem 1995, 
270:20242-20245.
Research Paper  Cbl and integrin-mediated cell adhesion Zell et al. 821
23. Fukazawa T, Reedquist KA, Trub T, Soltoff S, Panchamoorthy G,
Druker B, et al.: The SH3 domain-binding T cell tyrosyl
phosphoprotein p120. Demonstration of its identity with the c-cbl
protooncogene product and in vivo complexes with Fyn, Grb2, and
phosphatidylinositol 3-kinase. J Biol Chem 1995, 
270:19141-19150.
24. Buday L, Khwaja A, Sipeki S, Faragó A, Downward J: Interactions of
Cbl with two adaptor proteins, Grb2 and Crk, upon T cell
activation. J Biol Chem 1996, 271:6159-6163.
25. Rivero-Lezcano OM, Sameshima JH, Marcilla A, Robbins KC:
Physical association between Src homology 3 elements and the
protein product of the c-cbl proto-oncogene. J Biol Chem 1994,
269:17363-17366.
26. Kim TJ, Kim YT, Pillai S: Association of activated
phosphatidylinositol 3-kinase with p120cbl in antigen receptor-
ligated B cells. J Biol Chem 1995, 270:27504-27509.
27. Liu YC, Elly C, Yoshida H, Bonnefoy-Berard N, Altman A: Activation-
modulated association of 14-3-3 proteins with Cbl in T cells. J Biol
Chem 1996, 271:14591-14595.
28. Liu YC, Elly C, Langdon WY, Altman A: Ras-dependent, Ca2+-
stimulated activation of nuclear factor of activated T cells by a
constitutively active Cbl mutant in T cells. J Biol Chem 1997,
272:168-173.
29. Fitzer-Attas CJ, Schindler DG, Waks T, Eshhar Z: Direct T cell
activation by chimeric single chain Fv-Syk promotes Syk-Cbl
association and Cbl phosphorylation. J Biol Chem 1997,
272:8551-8557.
30. Schneider H, Prasad KVS, Shoelson SE, Rudd CE: CTLA-4 binding
to the lipid kinase phosphatidylinositol 3-kinase in T cells. J Exp
Med 1995, 181:351-355.
31. Nunès JA, Truneh A, Olive D, Cantrell DA: Signal transduction by
CD28 costimulatory receptor on T cells - B7-1 and B7-2
regulation of tyrosine kinase adaptor molecules. J Biol Chem
1996, 271:1591-1598.
32. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH,
Zvelebil MJ, et al.: p110d, a novel phosphoinositide 3-kinase in
leukocytes. Proc Natl Acad Sci USA 1997, 94:4330-4335.
33. Rameh LE, Chen CS, Cantley LC: Phosphatidylinositol (3,4,5)P3
interacts with SH2 domains and modulates PI 3-kinase
association with tyrosine-phosphorylated proteins. Cell 1995,
83:821-830.
34. Franke TF, Kaplan DR, Cantley LC, Toker A: Direct regulation of the
Akt proto-oncogene product by phosphatidylinositol-3,4-
bisphosphate. Science 1997, 275:665-668.
35. Andoniou CE, Thien CBF, Langdon WY: Tumour induction by
activated abl involves tyrosine phosphorylation of the product of
the cbl oncogene. EMBO J 1994, 13:4515-4523.
36. Thien CBF, Langdon WY: Tyrosine kinase activity of the EGF
receptor is enhanced by the expression of oncogenic 70Z-Cbl.
Oncogene 1997, 15:2909-2919.
37. Melendez AJ, Gillooly DJ, Harnett MM, Allen JM: Aggregation of the
human high affinity immunoglobulin G receptor (FcgRI) activates
both tyrosine kinase and G protein-coupled phosphoinositide 3-
kinase isoforms. Proc Natl Acad Sci USA 1998, 95:2169-2174.
38. Shimizu Y, Mobley JL, Finkelstein LD, Chan ASH: A role for
phosphatidylinositol 3-kinase in the regulation of b1 integrin
activity by the CD2 antigen. J Cell Biol 1995, 131:1867-1880.
39. Kinashi T, Escobedo JA, Williams LT, Takatsu K, Springer TA:
Receptor tyrosine kinase stimulates cell-matrix adhesion by
phosphatidylinositol 3 kinase and phospholipase C-g1 pathways.
Blood 1995, 86:2086-2090.
40. Yoon CH, Lee J, Jongeward GD, Sternberg PW: Similarity of sli-1, a
regulator of vulval development in C. elegans, to the mammalian
proto-oncogene c-cbl. Science 1995, 269:1102-1105.
41. Ueno H, Sasaki K, Miyagawa K, Honda H, Mitani K, Yazaki Y, et al.:
Antisense repression of proto-oncogene c-Cbl enhances
activation of the JAK-STAT pathway but not the Ras pathway in
epidermal growth factor receptor signaling. J Biol Chem 1997,
272:8739-8743.
42. Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM:
Maintenance of human T cell anergy: blocking of IL-2 gene
transcription by activated Rap1. Science 1997, 278:124-128.
43. Hunter AJ, Shimizu Y: a4b1-mediated tyrosine phosphorylation in
human T cells: characterization of Crk- and Fyn-associated
substrates (pp105, pp115, and human enhancer of filamentation-
1) and integrin-dependent activation of p59fyn. J Immunol 1997,
159:4806-4814.
822 Current Biology, Vol 8 No 14
Because Current Biology operates a ‘Continuous Publication
System’ for Research Papers, this paper has been published
on the internet before being printed. The paper can be
accessed from http://biomednet.com/cbiology/cub — for
further information, see the explanation on the contents page.
